Open AccessGene editing for corneal disease management
Author(s) -
Sudhanshu P. Raikwar,
Apoorva S Raikwar,
Shyam S Chaurasia,
Rajiv R. Mohan
Publication year - 2016
Publication title -
world journal of translational medicine
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2220-6132
DOI - 10.5528/wjtm.v5.i1.1
Subject(s) - genome editing , crispr , transcription activator like effector nuclease , zinc finger nuclease , biology , computational biology , regenerative medicine , genetic enhancement , genome , genome engineering , decipher , gene , bioinformatics , genetics , stem cell
Gene editing has recently emerged as a promising technology to engineer genetic modifications precisely in the genome to achieve long-term relief from corneal disorders. Recent advances in the molecular biology leading to the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) and CRISPR-associated systems, zinc finger nucleases and transcription activator like effector nucleases have ushered in a new era for high throughput in vitro and in vivo genome engineering. Genome editing can be successfully used to decipher complex molecular mechanisms underlying disease pathophysiology, develop innovative next generation gene therapy, stem cell-based regenerative therapy, and personalized medicine for corneal and other ocular diseases. In this review we describe latest developments in the field of genome editing, current challenges, and future prospects for the development of personalized gene-based medicine for corneal diseases. The gene editing approach is expected to revolutionize current diagnostic and treatment practices for curing blindness.